Guidant Revenue Advances 20% In Q2 Despite Struggles In U.S. Stent Market
Guidant's Vascular Intervention business will rely on sales of bare-metal stents outside the U.S., as the majority of the domestic market has converted to drug-eluting stents
Guidant's Vascular Intervention business will rely on sales of bare-metal stents outside the U.S., as the majority of the domestic market has converted to drug-eluting stents